Table 1. Main patients’ characteristics in the overall study population.
| Total (%) | |
|---|---|
| SEX | |
| Male | 82 (57) |
| Female | 62 (43) |
| Age | |
| Median (Range) | 62 (32–80) |
| <70 y.o | 123 (86) |
| ≥70 y.o | 21 (14) |
| RAS status | |
| WT | 58 (40) |
| MUT | 86 (60) |
| Previous anti-EGFR treatment | 58 (40) |
| Previous anti-VEGF treatment | 144 (100) |
| Previous lines of treatment | |
| 2 | 60 (41) |
| 3 | 62 (43) |
| 4 or more | 22 (16) |
| ECOG PS at treatment start | |
| 0 | 103 (72) |
| ≥1 | 41 (28) |
| 19 | |
| Baseline Blood Pressure | |
| Normal pressure | 62 (43) |
| Pre-existing hypertension managed by therapy | 82 (57) |
| Median OS | 6 months |
| Median PFS | 2.8 months |
| Response Rate | |
| PR | 9 (7.3) |
| SD | 37 (27) |
| PD | 86 (60) |
| NE | 12 (8) |
WT = wild type.
MUT = mutant.
EGFR = Epidermal Growth Factor Receptor.
VEGF = Vascular Endothelial Growth Factor.
ECOG PS = Overall Survival.
OS = Overall Survival.
PFS = Progression-Free Survival.
PR = Partial Remission.
SD = Stable Disease.
PD = Progressive Disease.
NE = Not Evaluated.